蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
12
返回列表 发新帖
楼主: 四叶花
收起左侧

[冻干] 单向流与层流有什么区别么?

  [复制链接]
药徒
发表于 2021-11-15 09:34:29 | 显示全部楼层
热血青年 发表于 2021-2-21 11:50
我又来挖坟了。
今天在看一个PDA对EU GMP2015无菌药品修订的建议时,看到这么一个描述:
3. 层流 vs. 单 ...

楼主是否可以分享下这个PDA的文章,多谢
回复

使用道具 举报

药徒
发表于 2021-11-15 17:13:00 | 显示全部楼层
xinhuawbo 发表于 2021-11-15 09:34
楼主是否可以分享下这个PDA的文章,多谢

找不到原文链接给你。但是可以提供原文参考:
Comments on the Annex 1 revision's concept paper are due March 31. Also, there will be another six months to comment after EMA and PIC/S issue a draft guideline in October. EMA and PIC/S previously revised the Annex 1 guideline in 1996, 2003 and 2007, but none of those revisions were as thorough as the one they' reconducting now.Why this revision? The guideline needs to reflect recent advances in technology as well as the International Conference on Harmonization's Q9 risk management and Q10 quality systems guidelines. There also are some historical inaccuracies and ambiguities in the document that the authorities intend to address.
Hopkins, an inspector with the United Kingdom's Medicines Healthcare products Regulatory Agency, added some reasons of his own. The industry is losing its technical skill level. Much work has shifted to emerging economies where manufacturers still are “learning by deficiencies.”
Also, there are new and emerging technologies, and areas still not covered by the guideline, such as media fills, small batches, active pharmaceutical ingredient campaigns, closed systems and blow fill seal technologies.
PDA established an expert group that began meeting in July and on March 13 issued Part 1 of a new two-part points-to-consider document. “Rather than just present what people are doing in the industry or what our position might be in regard to what regulators are asking for, what we decided to do was focus on real science,” PDA Chair Hal Baseman told reporters March 16 at the PDA annual meeting in Las Vegas.
One attendee speaking in a later session that day attributed this historical standard to the fan speed that happened to be available to the World War II Navy engineer who invented the HEPA filter.
“What is the state of the art there?” Baseman asked. “Well, the state of the art is not a number. The state of the art is to go in and look at your clean room operation, take a combination of dynamic air profile, smoke studies if you will, particulate levels, what's going on there, and devise from that what is the optimal velocity. … Today, the state of the art is to take a true risk-based design approach to it.”
Gabriele Gori, GSK Vaccines, who with Baseman co-chairs PDA's points-to-consider task force, on March 18 described key positions PDA is taking in Part 1 of its points-to-consider document and requested input on possible additional topics for Part 2. Gori also updated the PDA meeting on the work of another task force, co-chaired by Jette Christensen, Novo Nordisk, and Bob Darius, GSK, that is comparing three sterile manufacturing GMP guidelines –the 2004 FDA guidance,a 2011 World Health Organization technical report annex and the current 2008 version of the EU GMP Annex 1. PDA plans to publish that workgroup's detailed comparison in May with the idea of encouraging regulators to identify key differences between the documents and perhaps further align their expectations
PDA has so far developed 70 points consider, 38 of which it addressed in Part 1 of the document. Gori described some of the key positions in his remarks.
Airflow Velocity Measurements
Unlike other GMP guides, Annex 1 gives a value for airflow velocity at the working position rather than at the HEPA filter face. PDA accepts the value, 0.45 meters per second, plus or minus 20%, but wants it measured 15 to 30 centimeters from the filter face. The association would add that the airflow should be unidirectional and sufficient to protect exposed product as well as packaging components and surfaces that contact the product.
Grade A Environment Over Cappers
There is no need for Annex 1 to continue requiring Grade A air over capping stations outside the aseptic core, or, as PIC/S clarified in 2010, near the HEPA filters that supply air to the capping stations, PDA says.
Any vial that is properly stoppered in the aseptic core is adequately sealed against microbes while en route to the capping station, and can be capped under air that is merely HEPA filtered, PDA says.
In PDA's view, the key issue, Gori explained, is that “you have to have a sound automatic system to ensure that you are rejecting any vial which is not properly sealed by the stopper before it is crimped.”
Laminar vs. Unidirectional Airflow
PDA says Annex 1 should require unidirectional rather than laminar airflow in Grade A critical zones because laminar airflow is unnecessary and virtually impossible.
The key, the association said, is to establish unidirectional flow such that exposed product and sterile components always receive “first air” that hasn't passed any other component, operator or equipment that hasn't been sterilized. PDA adds that it believes turbulent airflow may be OK in closed isolators.
≥0.5μm and ≥5μm Total Particle Monitoring
Over the years, industry has chafed at the Annex 1 requirement to apply limits to air particles in Grade A environments and at-rest Grade B environments that are five microns or more in size.
Pointing to a draft ISO standard that says such particles are too few in such environments and too large for reliable sampling, PDA recommends merely trending such particle counts rather than setting a limit to them.
PDA agrees with the overlapping requirement for limits on particles that are 0.5 microns or larger.
Incubation Temperatures for Environmental Monitoring Samples
PDA recommends that manufacturers be expected to choose temperature regimens for environmental sample incubation that are appropriate for the microorganisms of concern, and suggests that the use of non-selective microbial growth media such as casein soya bean digest agar and a single temperature within a 20 to 35 degree C range, plus or minus 2.5 degrees, should suffice.
Pre-Use, Post Sterilization Integrity Test of Sterilizing Filters (PUPSIT)
PDA recommends case-by-case comprehensive risk assessments on whether to perform pre-use, post-sterilization integrity testing of sterilizing grade filters. The assessment should be done by line and by product, PDA says.
Such testing can prevent risk of contamination, but it also can introduce contamination. The bottom line for PDA is to avoid such testing if it increases overall risk to product quality.
The effect on business risk should only be considered in cases where testing doesn't increase the quality risk.
Use of Two Sterilizing Grade Filters for Product Sterile Filtration
PDA says the authorities should not require redundant sterilizing filters in series, but that use of filters in parallel can be appropriate. Regardless, sterilizing filters should be placed to minimize the number of downstream aseptic connections.
Methods of Production Requirements for Water for Injection
PDA recommends allowing the use of any validated method such as reverse osmosis for achieving sufficient quality for water for injection.
The European Pharmacopoeia only accepts the distillation method.
Gori cautioned the audience against adopting the PDA recommendations prematurely. “You still need to comply with the European requirements for the European markets, unless you have some investigator who's using common sense and accepts our interpretation.”

点评

非常感谢!  详情 回复 发表于 2021-11-16 09:46
回复

使用道具 举报

药徒
发表于 2021-11-16 09:46:06 | 显示全部楼层
热血青年 发表于 2021-11-15 17:13
找不到原文链接给你。但是可以提供原文参考:
Comments on the Annex 1 revision's concept paper are d ...

非常感谢!
回复

使用道具 举报

药徒
发表于 2021-11-16 09:57:35 | 显示全部楼层
一样的,说法差异,单向流更为合理一些
回复

使用道具 举报

药王
发表于 2023-4-25 20:28:26 | 显示全部楼层
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-10-9 04:11

Powered by Discuz! X3.4

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表